Wegovy success rate: what the clinical evidence shows

What the STEP 1 trial found, and how to read those numbers honestly

The STEP 1 trial enrolled 1,961 adults with obesity (BMI of 30 or above, or 27 or above with at least one weight-related condition) who did not have type 2 diabetes. After 68 weeks, those on semaglutide 2.4mg lost an average of around 14.9% of body weight compared with roughly 2.4% in the placebo arm. About a third of participants lost 20% or more of their starting weight. These figures come from the published STEP 1 paper in the New England Journal of Medicine, and they remain the foundation for understanding the semaglutide success rate.

One misconception worth setting aside gently: some people expect a single injection to produce rapid, dramatic results in the first few weeks. The titration schedule exists partly so the body adjusts, and meaningful weight change typically becomes apparent over months, not days. The trial ran for over a year precisely because sustained loss is the goal, not a quick drop that reverses.

Results were consistent across subgroups (men and women, different age ranges, different starting BMIs) though people with higher starting weights tended to lose more in absolute kilograms, while percentage loss was broadly similar. All participants received lifestyle counselling alongside the medicine, which matters: the NHS notes that semaglutide works as part of a reduced-calorie diet and increased activity, not instead of them.

What the newer 7.2mg evidence adds to the picture

In January 2026, the MHRA approved a 7.2mg semaglutide dose for adults with a BMI of 30 or above. Trials at this higher maintenance dose reported average weight loss of around 20.7% over 72 weeks, a figure that narrows the gap with tirzepatide's headline results considerably. A dedicated single-dose 7.2mg pen was approved by the MHRA in April 2026, designed to deliver the full weekly dose in one injection once a patient has titrated up from the standard 0.25mg starting point.

This matters for anyone weighing up the semaglutide evidence: the success rate question now has more than one answer depending on which dose and which trial period you're looking at. The 2.4mg figure from STEP 1 is still the most widely studied; 7.2mg data is newer and comes from a smaller pool of follow-up work. A prescriber reviewing your case can discuss which dose trajectory is appropriate for you, because the decision is not one-size-fits-all.

If you are comparing Wegovy directly against tirzepatide (Mounjaro), the SURMOUNT-5 head-to-head trial published in 2025 found tirzepatide produced greater average weight reduction than semaglutide 2.4mg over 72 weeks. The 7.2mg dose narrows that difference, though formal head-to-head evidence at 7.2mg against tirzepatide's highest doses is still emerging. Our weight-loss treatment overview covers how the two medicines compare if that question is front of mind.

What predicts a good response to Wegovy?

Trial averages describe populations, not individuals. Within STEP 1, some participants lost well over 20% of their body weight while others lost considerably less. Several factors are associated with better outcomes in the published data: lower baseline BMI (giving more room for percentage change), consistent lifestyle changes running alongside treatment, and staying on the medicine long enough for the full titration schedule to complete.

Stopping early is one of the clearest predictors of weight returning. Research across GLP-1 medicines consistently shows that weight regain begins when treatment stops, which is why stopping and restarting Wegovy is a topic our prescribers are asked about regularly. NICE guidance specifies that semaglutide use should be reviewed if less than 5% weight loss occurs after six months at the maintenance dose, a built-in checkpoint that keeps treatment purposeful rather than open-ended.

Side effects also influence outcomes indirectly. The most common are gastrointestinal (nausea, constipation, and similar effects) and these are most noticeable when doses increase, often settling within a couple of weeks. Severe or persistent symptoms should be discussed with a prescriber promptly; the NHS tirzepatide and semaglutide medicines guidance covers what to watch for. For practical advice on getting the most from treatment, the tips for Wegovy success page pulls together the evidence-backed lifestyle factors that the trials show make a real difference.

NHS access, private routes, and what success looks like in practice

NICE recommends semaglutide for weight management only within a specialist service offering multidisciplinary support, and currently for a maximum of two years. NHS waiting lists for those services are long in many areas. Private treatment through a regulated online pharmacy is how most people access Wegovy without that wait, provided a prescriber assesses suitability first and ongoing clinical review continues through treatment.

Understanding what a realistic outcome looks like matters before you start. The Wegovy weight-loss success page explores what the evidence says about long-term outcomes, and how to make the most of treatment covers the practical side of building on trial-level results in real life. If you are ready to find out whether Wegovy is clinically suitable for you, check your eligibility through a free consultation with our GPhC-registered prescribers.